New cocktail targets Hard-to-Treat stomach cancer
NCT ID NCT05632939
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal junction cancer that cannot be surgically removed. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASKB589 (a monoclonal antibody targeting CLDN18.2) combined with chemotherapy (oxaliplatin and capecitabine) and an immunotherapy (sintilimab or tislelizumab)
- What this could lead to
- If it works, this combination could offer a new first-line treatment option for people with advanced gastric cancer that cannot be removed by surgery.
- What could go wrong
- This is an early-phase trial with only 62 participants, so the main goal is safety and dosing—not yet proving the treatment works. Side effects from the drug combination could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100089, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?